Compare FMC Corp (FMC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs TransMedics Group Inc — how do they compare? FMC Corp trades at $8.95 (market cap $1.39B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and FMC Corp pays a 3.59% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and TransMedics Group Inc for 24 Days on average.
| FMC | TMDX | |
|---|---|---|
Market Cap | $1.39B | $2.74B |
Volume | 4,145,979 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $150.42 |
52-Week Low | $8.44 | $61.99 |
Typical Hold Time | 68 Days | 24 Days |
Enterprise Value | $5.19B | $3.13B |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $9.09, up 0.66% with bearish technical signals despite recent earnings beats. The agricultural sciences company faces severe profitability challenges with a -84.83% net margin and negative ROE, though valuation ratios appear attractive with P/S of 0.35 and P/B of 0.86. Recent developments include regulatory filings for new herbicides in Brazil and a minority equity investment from Tessenderlo Group.
While analyst consensus suggests moderate upside to the $14.60 price target, significant operational challenges and negative cash flow from operations in 2025 present substantial risks. The company's aggressive deleveraging efforts and new product pipeline offer potential catalysts, but investors face headwinds from cyclical industry pressures and persistent profitability issues.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
